- Home
- Publications
- Publication Search
- Publication Details
Title
Immunogenicity of biologic agents in rheumatology
Authors
Keywords
-
Journal
Nature Reviews Rheumatology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-12-14
DOI
10.1038/s41584-020-00540-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunogenicity of TNF-Inhibitors
- (2020) Sadaf Atiqi et al. Frontiers in Immunology
- Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD
- (2020) Evy Ulijn et al. ANNALS OF THE RHEUMATIC DISEASES
- Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies
- (2020) Takashi Kei Kishimoto Frontiers in Immunology
- Pretreatment and Coadministration With Methotrexate Improved Durability of Pegloticase Response
- (2020) John K. Botson et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Immunogenicity assay development and validation for biologic therapy as exemplified by ustekinumab
- (2019) Sorwe Mojtahed Poor et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay
- (2019) Lea C. Berkhout et al. Science Translational Medicine
- Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept
- (2019) Thierry Dervieux et al. ANNALS OF THE RHEUMATIC DISEASES
- Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk
- (2019) Nicoletta Bivi et al. mAbs
- Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis
- (2019) A. Deodhar et al. JOURNAL OF RHEUMATOLOGY
- The Neonatal Fc Receptor (FcRn): A Misnomer?
- (2019) Michal Pyzik et al. Frontiers in Immunology
- Methotrexate Reduces the Clearance of Adalimumab by Increasing the Concentration of Neonatal Fc Receptor in Tissues
- (2019) Yuwei Deng et al. PHARMACEUTICAL RESEARCH
- Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
- (2019) Vibeke Strand et al. BIODRUGS
- The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients
- (2019) Lea C Berkhout et al. RHEUMATOLOGY
- Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition
- (2018) J. Goncalves et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies
- (2018) Karin A van Schie et al. ANNALS OF THE RHEUMATIC DISEASES
- Methotrexate and BAFF interaction prevents immunization against TNF inhibitors
- (2018) Samuel Bitoun et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab
- (2018) B. Gorovits et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes
- (2018) Hillel P. Cohen et al. DRUGS
- Editorial: Magnetic Resonance Imaging Signals in the Sacroiliac Joints of Healthy Athletes: Refining Disease Thresholds and Treatment Strategies in Axial Spondyloarthritis
- (2018) Christopher Ritchlin Arthritis & Rheumatology
- Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis
- (2018) Amanda Ricciuto et al. Journal of Crohns & Colitis
- Nobel work that galvanized an industry
- (2018) NATURE BIOTECHNOLOGY
- Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis
- (2018) Jocelyn Quistrebert et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Recapture and improved outcome of pegloticase response with methotrexate–A report of two cases and review of the literature
- (2018) Sarah Y. Bessen et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials
- (2018) Soumi Gupta et al. EBioMedicine
- Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment
- (2017) Joachim R. Kalden et al. Nature Reviews Rheumatology
- Assays for Infliximab Drug Levels and Antibodies: A Matter of Scales and Categories
- (2017) L. I. Bader et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Immunogenicity of Therapeutic Antibodies
- (2017) Karien Bloem et al. THERAPEUTIC DRUG MONITORING
- Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn’s disease: a systematic review and meta-analysis
- (2017) Karoline Freeman et al. BMJ Open
- Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors
- (2017) Moustafa Hamze et al. Frontiers in Immunology
- The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study
- (2017) Robert J. Moots et al. PLoS One
- High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort
- (2016) Meghna Jani et al. ANNALS OF THE RHEUMATIC DISEASES
- The changing landscape of biosimilars in rheumatology
- (2016) Thomas Dörner et al. ANNALS OF THE RHEUMATIC DISEASES
- Low immunogenicity of tocilizumab in patients with rheumatoid arthritis
- (2016) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals
- (2016) G. R. Gunn et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics
- (2016) Katherine L. Gill et al. CLINICAL PHARMACOKINETICS
- A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture Elution
- (2016) Talia M. Muram et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors
- (2016) Carl I. Webster et al. mAbs
- Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity
- (2016) Anette Karle et al. mAbs
- A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice
- (2016) Meghna Jani et al. RHEUMATOLOGY
- Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes
- (2016) Murli Krishna et al. Frontiers in Immunology
- Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange
- (2016) Karin A. van Schie et al. Scientific Reports
- Immunogenicity, drug trough levels and therapeutic response in patients with rheumatoid arthritis or ankylosing spondylitis after 24-week golimumab treatment
- (2015) Der-Yuan Chen et al. ANNALS OF THE RHEUMATIC DISEASES
- Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium
- (2015) B. Rup et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis
- (2015) David Ternant et al. CLINICAL PHARMACOKINETICS
- Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL
- (2015) Bárbara P. Fafá et al. CLINICAL RHEUMATOLOGY
- Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients
- (2015) Karien Bloem et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Ashkenazi Jewish Origin Protects Against Formation of Antibodies to Infliximab and Therapy Failure
- (2015) Bella Ungar et al. MEDICINE
- Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice
- (2015) Thierry Schaeverbeke et al. RHEUMATOLOGY
- Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study
- (2015) Ariana Montes et al. ARTHRITIS RESEARCH & THERAPY
- Clinical Utility of Random Anti-Tumor Necrosis Factor Drug-Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis
- (2015) Meghna Jani et al. Arthritis & Rheumatology
- Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy
- (2015) Herbert S. B. Baraf et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab
- (2015) Hsien-Yi Chiu et al. PLoS One
- Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial
- (2014) Casper Steenholdt et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up
- (2014) Erik H Vogelzang et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
- (2014) Gerd-Rűdiger Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study
- (2014) Roy Fleischmann et al. CURRENT MEDICAL RESEARCH AND OPINION
- Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis
- (2014) Diana Hernández-Flórez et al. RHEUMATOLOGY INTERNATIONAL
- Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients
- (2014) Michael S Hershfield et al. ARTHRITIS RESEARCH & THERAPY
- Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout
- (2014) Peter E Lipsky et al. ARTHRITIS RESEARCH & THERAPY
- A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies
- (2013) Sandra Garcês et al. ANNALS OF THE RHEUMATIC DISEASES
- Key findings towards optimising adalimumab treatment: the concentration–effect curve
- (2013) Mieke F Pouw et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up
- (2013) Eva L Kneepkens et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
- (2013) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity of therapeutic proteins: Influence of aggregation
- (2013) Kirsty D. Ratanji et al. Journal of Immunotoxicology
- Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
- (2013) Pauline A. van Schouwenburg et al. Nature Reviews Rheumatology
- Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
- (2013) Herbert SB Baraf et al. ARTHRITIS RESEARCH & THERAPY
- Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: Lessons learned from 10 years of clinical laboratory testing experience
- (2012) Deeksha S. Bali et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS
- Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective
- (2012) Fabien B Vincent et al. ANNALS OF THE RHEUMATIC DISEASES
- Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner
- (2012) Charlotte L Krieckaert et al. ANNALS OF THE RHEUMATIC DISEASES
- The role of biosimilars in the treatment of rheumatic diseases
- (2012) Thomas Dörner et al. ANNALS OF THE RHEUMATIC DISEASES
- Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation
- (2012) Pauline A van Schouwenburg et al. ANNALS OF THE RHEUMATIC DISEASES
- Transient Low-Dose Methotrexate Induces Tolerance to Murine Anti-Thymocyte Globulin and Together They Promote Long-Term Allograft Survival
- (2012) A. Joseph et al. JOURNAL OF IMMUNOLOGY
- When is switching warranted among biologic therapies in rheumatoid arthritis?
- (2012) Alan Reynolds et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients
- (2011) A Jamnitski et al. ANNALS OF THE RHEUMATIC DISEASES
- Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: A case series and cohort study
- (2011) L. A. Korswagen et al. ARTHRITIS AND RHEUMATISM
- Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?
- (2011) Klaus Bendtzen ARTHRITIS AND RHEUMATISM
- Pegloticase and Chronic Gout--Reply
- (2011) J. S. Sundy et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
- (2011) Geertje M. Bartelds JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
- (2010) A. Jamnitski et al. ANNALS OF THE RHEUMATIC DISEASES
- Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model
- (2010) A. Joseph et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Nathanael L. Dirks et al. CLINICAL PHARMACOKINETICS
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Ron J. Keizer et al. CLINICAL PHARMACOKINETICS
- Dealing with immunogenicity of biologicals: assessment and clinical relevance
- (2010) Gerrit J Wolbink et al. CURRENT OPINION IN RHEUMATOLOGY
- Human immunoglobulin allotypes
- (2010) Roy Jefferis et al. mAbs
- The immunogenicity of humanized and fully human antibodies
- (2010) Fiona A. Harding et al. mAbs
- Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
- (2009) G. M. Bartelds et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial
- (2008) Shumpei Yokota et al. LANCET
- Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment
- (2008) Jinhai Wang et al. NATURE BIOTECHNOLOGY
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
- (2007) Daniel Tracey et al. PHARMACOLOGY & THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search